• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Sonnet Biotherapeutics Holdings Inc (NQ: SONN )

    4.210 -0.120 (-2.77%)
    Streaming Delayed Price Updated: 3:59 PM EST, Nov 5, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about Sonnet Biotherapeutics Holdings Inc

    < Previous 1 2 3 Next >
    Sonnet BioTherapeutics Reports Third Quarter Fiscal Year 2024 Financial Results and Provides Corporate Update
    From Sonnet BioTherapeutics Holdings, Inc.
    Via GlobeNewswire
    Sonnet BioTherapeutics Reports Encouraging Data from Phase 1b/2a Clinical Trial of SON-080 in Chemotherapy-Induced Peripheral Neuropathy (CIPN) That Support Advancement into Phase 2 Study
    From Sonnet BioTherapeutics Holdings, Inc.
    Via GlobeNewswire
    Sonnet BioTherapeutics Announces Exercise of Warrants for $3.4 Million in Gross Proceeds
    From Sonnet BioTherapeutics Holdings, Inc.
    Via GlobeNewswire
    Sonnet BioTherapeutics Provides Fiscal Year 2023 Business Overview
    Via ACCESSWIRE
    Sonnet BioTherapeutics Announces the Generation and Characterization of Two Novel Immunotherapeutic Pipeline Drug Candidates, SON-1411 and SON-1400, Each Containing a Variant IL-18 Domain
    From Sonnet BioTherapeutics Holdings, Inc.
    Via GlobeNewswire
    Sonnet BioTherapeutics to Present SB221 as a Trial in Progress at the ASCO 2024 Annual Meeting
    From Sonnet BioTherapeutics Holdings, Inc.
    Via GlobeNewswire
    Sonnet BioTherapeutics Announces Review of Strategic Alternatives
    Via ACCESSWIRE
    Sonnet BioTherapeutics Announces Updated Clinical Data for SON-1010 as Monotherapy or Combined with an anti-PD-L1, along with an Increase in the Dose-Escalation Target
    Via ACCESSWIRE
    Sonnet BioTherapeutics Provides Fiscal Year 2024 Second Quarter and Year-to-Date Business and Earnings Update
    Via ACCESSWIRE
    Sonnet BioTherapeutics Announces Participation in the EF Hutton Annual Global Conference
    Via ACCESSWIRE
    Sonnet BioTherapeutics to Present Preclinical Data on SON-080 for Chemotherapy-Induced Peripheral Neuropathy (CIPN) at the AACR 2024 Annual Meeting
    Via ACCESSWIRE
    Sonnet BioTherapeutics Announces Early Safety Data from the Company’s Phase 1b/2a Clinical Trial of SON-080 in Chemotherapy-Induced Peripheral Neuropathy (CIPN) Met the Study’s Initial Pre-Specified Objective
    Via ACCESSWIRE
    Sonnet BioTherapeutics Announces a Publication Demonstrating Safety and Tolerability of SON-1010 in Healthy Volunteers
    Via ACCESSWIRE
    Sonnet BioTherapeutics Provides Fiscal Year 2024 First Quarter Business and Earnings Update
    Via ACCESSWIRE
    Sonnet BioTherapeutics Announces Publication Demonstrating Suitability of SON-1210, the First Albumin-binding Bifunctional IL-12/IL-15 Fusion Protein, for Solid Tumor Immunotherapy
    Via ACCESSWIRE
    Sonnet BioTherapeutics Provides Fiscal Year 2023 Business and Financial Update
    Via ACCESSWIRE
    Sonnet BioTherapeutics Announces Pricing of $4.55 Million Underwritten Public Offering
    Via ACCESSWIRE
    Sonnet BioTherapeutics Announces Abstract Accepted for Presentation by a Key Opinion Leader at the 2023 Connective Tissue Oncology Society (CTOS) Annual Meeting
    Via ACCESSWIRE
    Sonnet BioTherapeutics Announces Results of Biodistribution Studies Demonstrating Solid Tumor Targeting Using the FHAB Technology
    Via ACCESSWIRE
    Sonnet BioTherapeutics Regains Nasdaq Minimum Bid Price Compliance
    Via ACCESSWIRE
    Sonnet BioTherapeutics Announces 1-for-22 Reverse Stock Split
    Via ACCESSWIRE
    Sonnet BioTherapeutics Announces FDA Acceptance of the Company's IND for the SB221 Clinical Trial of SON-1010 Combined with Atezolizumab in the US
    Via ACCESSWIRE
    Sonnet BioTherapeutics Provides Fiscal Year 2023 Third Quarter Business and Earnings Update
    Via ACCESSWIRE
    Sonnet BioTherapeutics to Present at the 2023 BTIG Virtual Biotechnology Conference
    Via ACCESSWIRE
    Sonnet BioTherapeutics Announces $2.25 Million Registered Direct Offering and Concurrent Private Placement
    Via ACCESSWIRE
    Sonnet BioTherapeutics Announces Presentations at the 2023 Cytokine-Based Drug Development Summit and Provides Preliminary Update on the SON-080 Study in Chemotherapy-Induced Peripheral Neuropathy
    Via ACCESSWIRE
    Sonnet BioTherapeutics Announces Regulatory Approval for Initiation of a Clinical Trial of SON-1010 Combined with Atezolizumab
    Via ACCESSWIRE
    Sonnet BioTherapeutics Provides Fiscal Year 2023 Second Quarter and Year-to-Date Business and Earnings Update
    Via ACCESSWIRE
    Sonnet BioTherapeutics Announces Updated Clinical Data for SON-1010 at the 2023 American Association for Cancer Research (AACR) Annual Meeting
    Via ACCESSWIRE
    Sonnet BioTherapeutics Announces Webcast to Discuss Clinical Data from the SB101 Study with SON-1010 Being Presented at the AACR 2023 Annual Meeting
    Via ACCESSWIRE
    < Previous 1 2 3 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.